Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PluvEquity: Pluvicto in African American Men With mCRPC
NCT07860554Phase 2Not yet recruiting
- Sponsor
- Emory University
- Start
- Nov 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lutetium lu 177 vipivotide tetraxetan in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Emory University. Primary endpoint: Radiographic Progression-Free Survival up to 36 months. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
lutetium lu 177 vipivotide tetraxetan
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT07860554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07860554.